The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients, finds a study published by The BMJ today.
Eve…
This is of exceptional public interest value. Ought to be di…
Home
Feed
Search
Library
Download